
    
      This is multicenter placebo-controlled study evaluating the safety and efficacy of a 14-day
      treatment of AI at two dosage levels as compared to placebo, given twice daily, in CF
      patients with P. aeruginosa lung infection, delivered by the eFlow investigational nebulizer.
    
  